This stage migration is seen in prostate cancer where a proportion of high-risk localized prostate cancer patients that are negative with conventional imaging but demonstrate metastases on PSMA PET/CT are reclassified to the oligometastatic cohort of patients. The gene discussed is FOLH1; the disease is prostate carcinoma.